Mistakes In… Mistakes In… Contents
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Rare Diseases: GI/Metabolic
Rare Diseases: GI / Metabolic Ciara Kennedy, PhD, MBA – Head of Cholestatic Liver Disease David Piccoli, MD – Chief of Gastroenterology, Hepatology & Nutrition, Children’s Hospital Of Philadelphia Our purpose We enable people with life-altering conditions to lead better lives. The “SAFE HARBOR” Statement Under the Private Securities Litigation Reform Act of 1995 Statements included in this announcement that are not historical facts are forward-looking statements. Forward-looking statements can be identified by words such as “aspiration”, “will”, “expect”, “forecast”, “aspiration”, “potential”, “estimates”, “may”, “anticipate”, “target”, “project” or similar expressions suitable for identifying information that refers to future events. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that: . Shire’s products may not be a commercial success; . revenues from ADDERALL XR are subject to generic erosion and revenues from INTUNIV will become subject to generic competition starting in December 2014; . the failure to obtain and maintain reimbursement, or an adequate level of reimbursement, by third-party payors in a timely manner for Shire's products may impact future revenues, financial condition and results of operations; . Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contractors to manufacture other products and to provide goods and services. Some of Shire’s products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire’s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time. -
European Guideline Chronic Pruritus Final Version
EDF-Guidelines for Chronic Pruritus In cooperation with the European Academy of Dermatology and Venereology (EADV) and the Union Européenne des Médecins Spécialistes (UEMS) E Weisshaar1, JC Szepietowski2, U Darsow3, L Misery4, J Wallengren5, T Mettang6, U Gieler7, T Lotti8, J Lambert9, P Maisel10, M Streit11, M Greaves12, A Carmichael13, E Tschachler14, J Ring3, S Ständer15 University Hospital Heidelberg, Clinical Social Medicine, Environmental and Occupational Dermatology, Germany1, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Poland2, Department of Dermatology and Allergy Biederstein, Technical University Munich, Germany3, Department of Dermatology, University Hospital Brest, France4, Department of Dermatology, Lund University, Sweden5, German Clinic for Diagnostics, Nephrology, Wiesbaden, Germany6, Department of Psychosomatic Dermatology, Clinic for Psychosomatic Medicine, University of Giessen, Germany7, Department of Dermatology, University of Florence, Italy8, Department of Dermatology, University of Antwerpen, Belgium9, Department of General Medicine, University Hospital Muenster, Germany10, Department of Dermatology, Kantonsspital Aarau, Switzerland11, Department of Dermatology, St. Thomas Hospital Lambeth, London, UK12, Department of Dermatology, James Cook University Hospital Middlesbrough, UK13, Department of Dermatology, Medical University Vienna, Austria14, Department of Dermatology, Competence Center for Pruritus, University Hospital Muenster, Germany15 Corresponding author: Elke Weisshaar -
Update of the Guideline on Chronic Pruritus
Update of the Guideline on Chronic Pruritus Developed by the Guideline Subcommittee “Chronic Pruritus” of the European Dermatology Forum Subcommittee Members: Prof. Dr. Elke Weisshaar, Heidelberg (Germany) Prof. Dr. Sonja Ständer, Münster (Germany) Prof. Dr. Erwin Tschachler, Wien (Austria) Prof. Dr. Torello Lotti, Florence (Italy) Prof. Dr. Johannes Ring, Munich (Germany) Prof. Dr. Laurent Misery, Brest (France) Dr. Markus Streit, Aarau (Switzerland) Prof. Dr. Thomas Mettang, Wiesbaden (Germany) Prof. Dr. Jacek Szepietowski, Wroclaw (Poland) Prof. Dr. Joanna Wallengren, Lund (Sweden) Dr. Peter Maisel, Münster (Germany) Prof. Dr. Uwe Gieler, Gießen (Germany) Prof. Dr. Malcolm Greaves (Singapore) Prof. Dr. Ulf Darsow, Munich (Germany) Prof. Dr. Julien Lambert, Antwerp (Belgium) Members of EDF Guideline Committee: Prof. Dr. Werner Aberer, Graz (Austria) Prof. Dr. Dieter Metze, Münster (Germany) Prof. Dr. Martine Bagot, Paris (France) Dr. Kai Munte, Rotterdam (Netherlands) Prof. Dr. Nicole Basset-Seguin, Paris (France) Prof. Dr. Gilian Murphy, Dublin (Ireland) Prof. Dr. Ulrike Blume-Peytavi, Berlin (Germany) Prof. Dr. Martino Neumann, Rotterdam (Netherlands) Prof. Dr. Lasse Braathen, Bern (Switzerland) Prof. Dr. Tony Ormerod, Aberdeen (UK) Prof. Dr. Sergio Chimenti, Rome (Italy) Prof. Dr. Mauro Picardo, Rome (Italy) Prof. Dr. Alexander Enk, Heidelberg (Germany) Prof. Dr. Johannes Ring, Munich (Germany) Prof. Dr. Claudio Feliciani, Rome (Italy) Prof. Dr. Annamari Ranki, Helsinki (Finland) Prof. Dr. Claus Garbe, Tübingen (Germany) Prof. Dr. Berthold Rzany, Berlin (Germany) Prof. Dr. Harald Gollnick, Magdeburg (Germany) Prof. Dr. Rudolf Stadler, Minden (Germany) Prof. Dr. Gerd Gross, Rostock (Germany) Prof. Dr. Sonja Ständer, Münster (Germany) Prof. Dr. Vladimir Hegyi, Bratislava (Slovakia) Prof. Dr. Eggert Stockfleth, Berlin (Germany) Prof. Dr. -
Pruritus Ani (Itchy Bottom)
PRURITUS ANI (ITCHY BOTTOM) What is pruritus ani? Pruritus ani means a chronic (persistent) itchy feeling around the anus. The main symptom is an urge to scratch your anus which is difficult to resist. The urge to scratch may occur at any time. However, it tends to be more common after you have been to the toilet to pass faeces, and at night (particularly just before falling asleep). The itch may be made worse by heat, wool, moisture, leaking, soiling, stress, and anxiety. About 1 in 20 people develop pruritus ani at some stage. It is common in both adults and children. What causes pruritus ani? Pruritus ani is a symptom, not a final diagnosis. Various conditions may cause pruritus ani. However, in many cases the cause is not clear. This is called ‘idiopathic pruritus ani’, which means ‘itchy anus of unknown cause’. Known causes of pruritus ani There are various causes which include the following: Inflamed anal skin is a common cause (a localised dermatitis). The inflammation is usually due to the skin ‘reacting’ to small amounts of faeces (sometimes called stools or motions) left on the skin, and/or to sweat and moisture around the anus. Young children who may not wipe themselves properly, adults with sweaty jobs, and adults with a lot of hair round the anus may be especially prone to this. Thrush and fungal infections. These germs like it best in moist, warm, airless areas, such as around the anus. Thrush is more common in people with diabetes. Other infections such as scabies, herpes, anal warts and some other sexually transmitted diseases can cause itch around the anus. -
Baseline Levels of Endogenous Compounds in the Caucasian Population S
Feasibility assessment of PBPK modelling for Endogenous Compounds: Baseline levels of endogenous compounds in the Caucasian population S. Neuhoff, H.E. Humphries, H. K. Crewe, Z. E. Barter, and K. Rowland-Yeo Simcyp Ltd (a Certara company), Blades Enterprise Centre, Sheffield, S2 4SU [email protected] BACKGROUND RESULTS (cont) RESULTS (cont) • There is increasing interest in the • Bilirubin and glucuronides 27-Hydroxycholesterol potential utility of Endogenous Cholesterol 1g/day A schematic of the formation and Compounds (EC’s) as biomarkers for CYP7A1 (liver) 500 mg/day CYP27A1 (many tissues) breakdown of bilirubin is shown in assessment of drug-induced enzyme 19 mg/day Figure 4. Total serum bilirubin (bilirubin 7α-Hydroxycholesterol level/activity changes of (a) CYP3A or CYP3A4 + bilirubin glucuronide), conjugated and Bile Acids (b) UGT1A1 following chronic dosing of 4-Hydroxycholesterol unconjugated plasma levels reflect the drug of interest. CYP27A1 (liver and extrahepatic) 24S-Hydroxycholesterol protein changes differently. • In July 2013, Consortium Members Pregnenolone were asked to identify a series of EC’s 4,27-Dihydroxycholesterol Macrophage CYP27A1 • Biliverdin reductase reduces Heme Hemeoxygenase for further evaluation, with a view to 4,24-Dihydroxycholesterol Biliverdin to unconjugated, water- Biliverdin 4,7α-Dihydroxycholesterol insoluble Bilirubin, which is Biliverdin reductase implementation within the Simcyp Bilirubin carried in blood bound to serum Unconjugated bilirubin Simulator. albumin complexed with albumin 3 -
Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors
Pharmaceutics 2011 , 3, 615-635; doi:10.3390/pharmaceutics3030615 OPEN ACCESS pharmaceutics ISSN 1999-4923 www.mdpi.com/journal/pharmaceutics Review Transporter-Mediated Drug Interaction Strategy for 5-Aminolevulinic Acid (ALA)-Based Photodynamic Diagnosis of Malignant Brain Tumor: Molecular Design of ABCG2 Inhibitors Toshihisa Ishikawa 1,*, Kenkichi Takahashi 2, Naokado Ikeda 2, Yoshinaga Kajimoto 2, Yuichiro Hagiya 3, Shun-ichiro Ogura 3, Shin-ichi Miyatake 2 and Toshihiko Kuroiwa 2 1 Omics Science Center, RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, 230-0045, Japan 2 Department of Neurosurgery, Osaka Medical College, Osaka 569-8686, Japan 3 Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama 226-8501, Japan * Author to whom correspondence should be addressed: E-Mail: [email protected]; Tel.: +81-45-503-9222; Fax: +81-45-503-9216. Received: 19 July 2011; in revised form: 16 August 2011 / Accepted: 9 September 2011 / Published: 14 September 2011 Abstract: Photodynamic diagnosis (PDD) is a practical tool currently used in surgical operation of aggressive brain tumors, such as glioblastoma. PDD is achieved by a photon-induced physicochemical reaction which is induced by excitation of protoporphyrin IX (PpIX) exposed to light. Fluorescence-guided gross-total resection has recently been developed in PDD, where 5-aminolevulinic acid (ALA) or its ester is administered as the precursor of PpIX. ALA induces the accumulation of PpIX, a natural photo-sensitizer, in cancer cells. Recent studies provide evidence that adenosine triphosphate (ATP)-binding cassette (ABC) transporter ABCG2 plays a pivotal role in regulating the cellular accumulation of porphyrins in cancer cells and thereby affects the efficacy of PDD. -
Bilirubin Secretion, Jaundice and Evaluation of Liver Function
Bilirubin Secretion, Jaundice and Evaluation of Liver Function Howard J. Worman, M. D. Evaluation of Liver Disease and Hepatic Function History Physical Examination Laboratory Tests Sometimes Radiological/Nuclear Medicine Sometimes Liver Biopsy 1 Jaundice occurs as a result of excess bilirubin in the blood. It is a hallmark of liver disease but not always present in liver disease. Jaundice occurs when the liver fails to adequately secrete bilirubin from the blood into the bile. To understand how jaundice occurs, you must first understand bilirubin synthesis, metabolism and secretion. 2 Heme Oxygenase Schuller et al. Nature Structural Biology 6, 860 - 867 (1999) Bilivirdin Reductase Kikuchi et al. Nature Structural Biology 8, 221 - 225 (2001) 3 Bilirubin is frequently depicted as a linear tetrapyrrole. However, intramolecular hydrogen bonding fixes it in a rigid structure that blocks exposure of its polar groups to aqueous solvents, making it very insoluble in blood. 4 Bilirubin in Blood is Bound to Albumin: Uptake into Hepatocyte at Basolateral (Sinusoidal) Membrane Some OATP-C? bilirubin stored in cytosol bound to proteins Bilurubin UDP-glucuronosyltransferase is localized to the endo- plasmic reticulum; it catalyzes conjugation to a diglucuronide, making it more water soluble. A: Labeling of periphery of cell hepatocyte nucleus B: Labeling of ER with antibody to UDP-glucuronosyltransferase 5 Alternative RNA splicing of different first exons of UGT1 gives different isoforms with different substrate specificities, some for bilirubin and others -
European Guideline on Chronic Pruritus in Cooperation with the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV)
European Guideline on Chronic Pruritus In cooperation with the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV) Weisshaar, Elke; Szepietowski, Jacek C.; Darsow, Ulf; Misery, Laurent; Wallengren, Joanna; Mettang, Thomas; Gieler, Uwe; Lotti, Torello; Lambert, Julien; Maisel, Peter; Streit, Markus; Greaves, Malcolm W.; Carmichael, Andrew; Tschachler, Erwin; Ring, Johannes; Staenders, Sonja Published in: Acta Dermato-Venereologica DOI: 10.2340/00015555-1400 2012 Link to publication Citation for published version (APA): Weisshaar, E., Szepietowski, J. C., Darsow, U., Misery, L., Wallengren, J., Mettang, T., Gieler, U., Lotti, T., Lambert, J., Maisel, P., Streit, M., Greaves, M. W., Carmichael, A., Tschachler, E., Ring, J., & Staenders, S. (2012). European Guideline on Chronic Pruritus In cooperation with the European Dermatology Forum (EDF) and the European Academy of Dermatology and Venereology (EADV). Acta Dermato-Venereologica, 92(5), 563- 581. https://doi.org/10.2340/00015555-1400 Total number of authors: 16 General rights Unless other specific re-use rights are stated the following general rights apply: Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Read more about Creative commons licenses: https://creativecommons.org/licenses/ LUND UNIVERSITY Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. -
Pharmacological Interventions for Pruritus in Adult Palliative Care Patients (Review)
Cochrane Database of Systematic Reviews Pharmacological interventions for pruritus in adult palliative care patients (Review) Siemens W, Xander C, Meerpohl JJ, Buroh S, Antes G, Schwarzer G, Becker G Siemens W, Xander C, Meerpohl JJ, Buroh S, Antes G, Schwarzer G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD008320. DOI: 10.1002/14651858.CD008320.pub3. www.cochranelibrary.com Pharmacological interventions for pruritus in adult palliative care patients (Review) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 9 METHODS ...................................... 9 RESULTS....................................... 15 Figure1. ..................................... 16 Figure2. ..................................... 22 Figure3. ..................................... 23 ADDITIONALSUMMARYOFFINDINGS . 34 DISCUSSION ..................................... 54 AUTHORS’CONCLUSIONS . 57 ACKNOWLEDGEMENTS . 58 REFERENCES ..................................... 59 CHARACTERISTICSOFSTUDIES . 69 DATAANDANALYSES. 164 Analysis 1.1. Comparison 1 Naltrexone versus placebo, Outcome 1 A) Pruritus on VAS scale (0-10 cm) in CP participants. ................................. -
Pruritus Ani Fact Sheet
PRURITUS ANI FACT SHEET What is Pruritus Ani? Pruritus Ani is an intense itching sensation at or near the anus. What causes Pruritus Ani? The most common cause of anal itching is excessive anal cleaning. Other less common causes include: Irritation: soaps, scented toilet tissue, feminine hygiene products, and creams or ointments can bring about the condition. Diet: foods containing caffeine may cause and/or contribute to Pruritus Ani. Coffee, tea, colas, and chocolate have caffeine. Other offenders may include tomatoes, ketchup, milk products and beer. Diarrhea: Pruritus Ani can be caused or aggravated by loose, runny stools. Anxiety: nervous tension and stress may cause or worsen anal itching. Other rare causes of Pruritus Ani include psoriasis, yeast infections, pinworms and contact dermatitis. How is Pruritus Ani treated? If you are experiencing an intense itching sensation in or near your anus, consult with your physician for proper diagnosis. He or she may recommend the following: • No soap – use only water when washing the anal area, keeping it as clean as possible. • Avoid the previously mentioned foods and beverages. • Avoid foods and beverages which may cause diarrhea. • Stop the use of medications and ointments on the anal area, except when prescribed by your physician. • Wear cotton undergarments. Pruritus Ani symptoms do not disappear immediately. Patience, following the above instructions and seeing your physician for a follow-up examination can eliminate your problems with anal itching. Fox Valley Surgical Associates 1818 N. Meade Street, Suite 240 West | Appleton, WI 54911 (920) 731-8131 or (800) 574-3872 www.fvsa-wi.com. -
Inherited Disorders of Bilirubin Clearance N
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Hofstra Northwell Academic Works (Hofstra Northwell School of Medicine) Donald and Barbara Zucker School of Medicine Journal Articles Academic Works 2015 Inherited disorders of bilirubin clearance N. Memon B. I. Weinberger Zucker School of Medicine at Hofstra/Northwell T. Hegyi L. M. Aleksunes Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles Part of the Pediatrics Commons Recommended Citation Memon N, Weinberger B, Hegyi T, Aleksunes L. Inherited disorders of bilirubin clearance. 2015 Jan 01; 79(3):Article 2776 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/2776. Free full text article. This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact [email protected]. HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pediatr Manuscript Author Res. Author manuscript; Manuscript Author available in PMC 2016 April 05. Published in final edited form as: Pediatr Res. 2016 March ; 79(3): 378–386. doi:10.1038/pr.2015.247. Inherited Disorders of Bilirubin Clearance Naureen Memon1,*, Barry I Weinberger2, Thomas Hegyi1, and Lauren M Aleksunes3 1Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA 2Department of Pediatrics, Cohen Children’s Medical Center of New York, New Hyde Park, NY, USA 3Department of Pharmacology and Toxicology, Rutgers University, Piscataway, NJ, USA Abstract Inherited disorders of hyperbilirubinemia may be caused by increased bilirubin production or decreased bilirubin clearance. -
Chapter 5 – Gastrointestinal System
CHAPTER 5 – GASTROINTESTINAL SYSTEM First Nations and Inuit Health Branch (FNIHB) Clinical Practice Guidelines for Nurses in Primary Care. The content of this chapter was revised October 2011. Table of Contents ASSESSMENT OF THE GASTROINTESTINAL SYSTEM ......................................5–1 EXAMINATION OF THE ABDOMEN ........................................................................5–2 COMMON PROBLEMS OF THE GASTROINTESTINAL SYSTEM .........................5–4 Anal Fissure .......................................................................................................5–4 Constipation .......................................................................................................5–5 Dehydration (Hypovolemia) ...............................................................................5–8 Diarrhea ...........................................................................................................5–11 Diverticular Disease .........................................................................................5–15 Diverticulitis ......................................................................................................5–15 Diverticulosis ....................................................................................................5–16 Dyspepsia ........................................................................................................5–17 Gallbladder Disease .........................................................................................5–18 Biliary Colic ......................................................................................................5–21